文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

磁共振引导立体定向再照射治疗局部复发前列腺癌的长期结果

Magnetic resonance guided stereotactic reirradiation for locally recurrent prostate cancers: Long-term results from a prospective registry study.
PubMed 文献 · Radiother Oncol · 2025-08-13

这项前瞻性登记研究纳入108例局部复发前列腺癌患者,分别接受5×6 Gy(67例)或6×6 Gy(41例)磁共振引导放疗再照射。中位随访31.9个月,两组中位生化无复发生存期分别为18.3个月和22.8个月(p=0.32),5×6 Gy组出现3例3级晚期泌尿生殖毒性。结论认为MRgRT再照射有效,剂量提升结果良好且毒性低。

要点

  • 5×6 Gy组中位bRFS为18.3个月,6×6 Gy组为22.8个月,差异无统计学意义。
  • PSA倍增时间与bRFS显著相关(p=0.04)。
  • 5×6 Gy组出现3例3级晚期泌尿生殖毒性,6×6 Gy组未报告。

核心结论

  • MRgRT再照射是局部复发前列腺癌的有效治疗,剂量提升显示出良好结果且毒性低,需更大前瞻性研究验证。

研究设计与样本

  • 前瞻性登记研究,纳入108例接受MRgRT的局部复发前列腺癌患者,分为5×6 Gy组(67例)和6×6 Gy组(41例)。

主要发现

  • 5×6 Gy组中位bRFS为18.3个月(95%CI 15.0-24.3),6×6 Gy组为22.8个月(95%CI 18.3-未达到),p=0.32。
  • 5×6 Gy组中位lRFS为25.3个月(95%CI 18.5-NA),6×6 Gy组未达到(p=0.07)。
  • PSA倍增时间与bRFS显著相关(p=0.04)。
  • 5×6 Gy组出现3例3级晚期泌尿生殖毒性。

关键数值与推荐

  • 5×6 Gy组和6×6 Gy组的中位随访分别为50.0个月(范围4-63)和17.2个月(范围1.5-34),总体为31.9个月(范围1.5-63)。
  • 毒性按CTCAE v5.0评估。

临床怎么用

  • 对于根治性前列腺切除或放疗后局部复发的前列腺癌,MRgRT再照射可作为姑息性ADT之外的治疗选择。
  • 剂量提升至6×6 Gy可能改善bRFS和lRFS,但需注意晚期泌尿生殖毒性。

局限性

  • 两组随访时间不均衡,6×6 Gy组随访明显短于5×6 Gy组。
  • 样本量有限,需更大前瞻性研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Local recurrence is the most common site for prostate cancer after radical prostatectomy (RP) or radiation therapy. Treatment beyond palliative androgen deprivation therapy (ADT) are required. Stereotactic reirradiation using magnetic resonance-guided radiation therapy (MRgRT) emerged as a promising approach. This study assessed the outcomes and toxicities of 5 × 6 Gy and 6 × 6 Gy MRgRT for local-only recurrences. MATERIALS AND METHODS: 108 patients treated with MRgRT were included and divided into two groups: 5 × 6 Gy (67 patients) and 6 × 6 Gy (41 patients). The primary endpoint was biochemical recurrence-free survival (bRFS). Secondary endpoints included local recurrence free-survival (lRFS), metastasis-free survival (MFS), overall survival (OS) rates, and treatment toxicities. Toxicity was assessed according to CTCAE v5.0. RESULTS: The median follow-up was 31.9 months (range 1.5-63): 50.0 months (range 4-63) in the 5 × 6 Gy group and 17.2 months (range 1.5-34) in the 6 × 6 Gy group. The median bRFS was 18.3 months (95 % CI: 15.0 - 24.3) and 22.8 months (95 % CI: 18.3-not reached) in the 5 × 6 Gy and 6 × 6 Gy groups, respectively (p = 0.32). The median lRFS was 25.3 months (95 % CI: 18.5 - NA) in the 5 × 6 Gy group and was not reached in the 6 × 6 Gy group (p = 0.07). PSA doubling-time was statistically associated with bRFS (p = 0.04). Three cases of grade 3 late genitourinary toxicity appeared in the 5 × 6 Gy group. CONCLUSION: Reirradiation with MRgRT is an effective treatment for locally recurrent prostate cancer. Dose escalation showed promising outcomes with low toxicity, highlighting the need for larger prospective studies.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Buchalet C, Riou O, Colin R, et al. Magnetic resonance guided stereotactic reirradiation for locally recurrent prostate cancers: Long-term results from a prospective registry study. Radiother Oncol. 2025. PMID: 40816463. doi:10.1016/j.radonc.2025.111087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。